tiprankstipranks
Enliven initiated with a Buy at Mizuho
The Fly

Enliven initiated with a Buy at Mizuho

Mizuho initiated coverage of Enliven Therapeutics with a Buy rating and $34 price target. The company has validated biology, differentiated chemistry and disciplined trial design to bring new life to standards of care, the analyst telsl investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles